Shots:
- The US FDA has granted 510(k) clearance to Encora X1 to help relieve hand tremors in the treated limb during stimulation in adults with essential tremor
- Clearance was backed by a sham-controlled trial & a 90-day home-use study, both demonstrating improvements in tremor severity & functional tasks, supporting the device’s ability to assist with daily activities such as eating, drinking, & writing
- Encora X1 is a noninvasive, wrist-worn neurostimulation device that detects tremor rhythm & delivers tailored stimulation to disrupt tremor signals, improving stability & motor control during daily tasks
Ref: Businesswire | Image: Encora Therapeutics | Press Release
Related News: Labcorp Launches Elecsys pTau-181 Test to Help Rule Out Alzheimer’s Disease in the US
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
